7/11/2013

Stem cell startup ViaCyte secured $10.6 million in a private equity funding round in which Johnson & Johnson, the Johnson Trust and Sanderling Ventures participated. The funding matches the $10.1 million grant approved last year by the California Institute for Regenerative Medicine to support clinical trials of ViaCyte's encapsulated cell therapy product, VC-01, for treatment of type 1 and insulin-dependent type 2 diabetes.

Full Story:
Xconomy

Related Summaries